Fulgent Genetics, Inc. (NASDAQ:FLGT) Insider Hanlin Gao Sells 1,039 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) insider Hanlin Gao sold 1,039 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $20.54, for a total value of $21,341.06. Following the transaction, the insider now directly owns 962,035 shares of the company's stock, valued at $19,760,198.90. This represents a 0.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Fulgent Genetics Price Performance

Shares of NASDAQ FLGT remained flat at $20.61 during mid-day trading on Friday. The stock had a trading volume of 368,147 shares, compared to its average volume of 280,781. Fulgent Genetics, Inc. has a twelve month low of $14.57 and a twelve month high of $25.11. The firm has a market cap of $627.45 million, a PE ratio of -3.73 and a beta of 1.00. The business's 50-day moving average is $18.76 and its 200 day moving average is $18.06.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings data on Friday, May 2nd. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.22. Fulgent Genetics had a negative net margin of 59.39% and a negative return on equity of 1.81%. The company had revenue of $73.46 million during the quarter, compared to analyst estimates of $71.26 million. During the same period in the prior year, the firm earned ($0.01) earnings per share. The business's quarterly revenue was up 14.0% on a year-over-year basis. As a group, equities analysts expect that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.

Analyst Ratings Changes

FLGT has been the subject of a number of research analyst reports. Piper Sandler reissued a "neutral" rating and issued a $23.00 price target (up from $16.00) on shares of Fulgent Genetics in a report on Tuesday, May 6th. Raymond James reiterated an "outperform" rating and issued a $25.00 target price (up from $24.00) on shares of Fulgent Genetics in a report on Monday, May 5th. Finally, Wall Street Zen upgraded shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday, March 5th.

Institutional Investors Weigh In On Fulgent Genetics

Several hedge funds have recently made changes to their positions in FLGT. Millennium Management LLC grew its position in Fulgent Genetics by 28.6% during the 1st quarter. Millennium Management LLC now owns 1,969,433 shares of the company's stock worth $33,283,000 after purchasing an additional 437,632 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Fulgent Genetics by 124.0% in the first quarter. Acadian Asset Management LLC now owns 805,941 shares of the company's stock worth $13,611,000 after buying an additional 446,076 shares during the period. Geode Capital Management LLC grew its holdings in shares of Fulgent Genetics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 514,152 shares of the company's stock valued at $9,499,000 after buying an additional 11,283 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Fulgent Genetics by 40.8% during the fourth quarter. Ameriprise Financial Inc. now owns 501,809 shares of the company's stock valued at $9,268,000 after buying an additional 145,518 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Fulgent Genetics by 39.4% during the fourth quarter. JPMorgan Chase & Co. now owns 471,259 shares of the company's stock valued at $8,704,000 after buying an additional 133,215 shares during the period. Hedge funds and other institutional investors own 48.06% of the company's stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.